Prediagnostic Antibody Responses to Fusobacterium nucleatum Proteins Are Not Associated with Risk of Colorectal Cancer in a Large U.S. Consortium.
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
- Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Population Science, American Cancer Society, Atlanta, Georgia.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
- Population Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
- University of Southern California Keck School of Medicine and University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
- Department of Population Health, New York University School of Medicine, New York, New York.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
- Division of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Centre for Public Health Research, Massey University, Wellington, New Zealand.
- Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.
- Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, Maryland.
- Infections and Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
- Cancer Control and Population Sciences Program, Duke Cancer Institute and Department of Population Health Sciences, Duke University, Durham, North Carolina.
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. msong@hsph.harvard.edu.
BACKGROUND: The association between prediagnostic antibody responses to Fusobacterium nucleatum (F. nucleatum) and subsequent risk of colorectal cancer is not established.
METHODS: We conducted a nested case-control study of 8,126 participants in a consortium of 10 prospective cohorts in the United States.
RESULTS: Higher seroprevalence of any F. nucleatum antibody was observed among non-White participants (51.1%) compared with White participants (31.2%). We did not find any statistically significant association between seropositivity to any of the eight F. nucleatum proteins and colorectal cancer risk.
CONCLUSIONS: Prediagnostic antibody responses to F. nucleatum proteins were not associated with the risk of colorectal cancer.
IMPACT: Future studies may consider a more specific detection of the immunoglobulin isotypes or focus on examining F. nucleatum in stool or tissue samples.
- 2013-0192: Helicobacter pylori and colorectal cancer risk (Meira Epplein - 2013)